Pulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy: Safety and feasibility.
adoptive cell therapy
postoperative outcomes
pulmonary metastasectomy
pulmonary resection
tumor-infiltrating lymphocyte
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
revised:
03
04
2021
received:
29
08
2020
accepted:
12
05
2021
pubmed:
1
6
2021
medline:
20
8
2021
entrez:
31
5
2021
Statut:
ppublish
Résumé
Adoptive T-cell therapies (ACTs) using expansion of tumor-infiltrating lymphocyte (TIL) populations are of great interest for advanced malignancies, with promising response rates in trial settings. However, postoperative outcomes following pulmonary TIL harvest have not been widely documented, and surgeons may be hesitant to operate in the setting of widespread disease. Patients who underwent pulmonary TIL harvest were identified, and postoperative outcomes were studied, including pulmonary, cardiovascular, infectious, and wound complications. 83 patients met inclusion criteria. Pulmonary TIL harvest was undertaken primarily via a thoracoscopy with a median operative blood loss and duration of 30 ml and 65 min, respectively. The median length of stay was 2 days. Postoperative events were rare, occurring in only five (6%) patients, including two discharged with a chest tube, one discharged with oxygen, one episode of urinary retention, and one blood transfusion. No reoperations occurred. The median time from TIL harvest to ACT infusion was 37 days. Pulmonary TIL harvest is safe and feasible, without major postoperative events in our cohort. All patients were able to receive intended ACT infusion without delays. Therefore, thoracic surgeons should actively participate in ongoing ACT trials and aggressively seek to enroll patients on these protocols.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Adoptive T-cell therapies (ACTs) using expansion of tumor-infiltrating lymphocyte (TIL) populations are of great interest for advanced malignancies, with promising response rates in trial settings. However, postoperative outcomes following pulmonary TIL harvest have not been widely documented, and surgeons may be hesitant to operate in the setting of widespread disease.
METHODS
METHODS
Patients who underwent pulmonary TIL harvest were identified, and postoperative outcomes were studied, including pulmonary, cardiovascular, infectious, and wound complications.
RESULTS
RESULTS
83 patients met inclusion criteria. Pulmonary TIL harvest was undertaken primarily via a thoracoscopy with a median operative blood loss and duration of 30 ml and 65 min, respectively. The median length of stay was 2 days. Postoperative events were rare, occurring in only five (6%) patients, including two discharged with a chest tube, one discharged with oxygen, one episode of urinary retention, and one blood transfusion. No reoperations occurred. The median time from TIL harvest to ACT infusion was 37 days.
CONCLUSIONS
CONCLUSIONS
Pulmonary TIL harvest is safe and feasible, without major postoperative events in our cohort. All patients were able to receive intended ACT infusion without delays. Therefore, thoracic surgeons should actively participate in ongoing ACT trials and aggressively seek to enroll patients on these protocols.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
699-703Subventions
Organisme : Mason Family Research Fund
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Joseph RW , Peddareddigari VR , Liu P , et al. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res. 2011;17(14):4882-4891.
Dudley ME , Wunderlich JR , Yang JC , et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002;25(3):243-251.
Dudley ME , Wunderlich JR , Shelton TE , Even J , Rosenberg SA . Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26(4):332-342.
Radvanyi LG , Bernatchez C , Zhang M , et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012;18(24):6758-6770.
Forget MA , Haymaker C , Hess KR , et al. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin Cancer Res. 2018;24(18):4416-4428.
Dudley ME , Yang JC , Sherry R , et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233-5239.
Saint-Jean M , Knol AC , Volteau C , et al. Adoptive cell therapy with tumor-infiltrating lymphocytes in advanced melanoma patients. J Immunol Res. 2018;2018:3530148.
Dafni U , Michielin O , Lluesma SM , et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann Oncol. 2019;30(12):1902-1913.
Goff SL , Smith FO , Klapper JA , et al. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother. 2010;33(8):840-847.
Van Haren RM , Mehran RJ , Mena GE , et al. Enhanced recovery decreases pulmonary and cardiac complications after thoracotomy for lung cancer. Ann Thorac Surg. 2018;106(1):272-279.
Geller AD , Zheng H , Mathisen DJ , Wright CD , Lanuti M . Relative incremental costs of complications of lobectomy for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2018;155(4):1804-1811.
Zippel D , Friedman-Eldar O , Rayman S , et al. Tissue harvesting for adoptive tumor infiltrating lymphocyte therapy in metastatic melanoma. Anticancer Res. 2019;39(9):4995-5001.
Treasure T , Farewell V , Macbeth F , et al. Pulmonary metastasectomy versus continued active monitoring in colorectal cancer (PulMiCC): a multicentre randomised clinical trial. Trials. 2019;20(1):718.
Handy JR , Bremner RM , Crocenzi TS , et al. Expert consensus document on pulmonary metastasectomy. Ann Thorac Surg. 2019;107(2):631-649.
Petersen RP , Hanish SI , Haney JC , et al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg. 2007;133(1):104-110.
Hanna TP , Chauvin C , Miao Q , et al. Clinical outcomes after pulmonary metastasectomy for melanoma: a population-based study. Ann Thorac Surg. 2018;106(6):1675-1681.
Chua TC , Scolyer RA , Kennedy CW , Yan TD , McCaughan BC , Thompson JF . Surgical management of melanoma lung metastasis: an analysis of survival outcomes in 292 consecutive patients. Ann Surg Oncol. 2012;19(6):1774-1781.
Guerrera F , Mossetti C , Ceccarelli M , et al. Surgery of colorectal cancer lung metastases: analysis of survival, recurrence and re-surgery. J Thorac Dis. 2016;8(7):1764-1771.
Casiraghi M , De Pas T , Maisonneuve P , et al. A 10-year single-center experience on 708 lung metastasectomies: the evidence of the “international registry of lung metastases”. J Thorac Oncol. 2011;6(8):1373-1378.
van Dorp M , Beck N , Steup WH , Schreurs WH . Surgical treatment of pulmonary metastases in the Netherlands: data from the Dutch Lung Cancer Audit for Surgery. Eur J Cardiothorac Surg. 2020;58:768-774.